US · MIR · INDUSTRIAL - MACHINERY
Mirion Technologies, Inc. (MIR) intrinsic value and stock valuation
$16.07as of 2026-11-21 · Mkt cap 3.75B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Mirion Technologies, Inc. DCF and intrinsic value
InvestorsCraft values MIR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MIR’s statements →
Mirion Technologies, Inc. Graham Number
Graham Number: $4.85d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Gates Industrial Corporation plc (GTES) $22.02
- EnPro Industries, Inc. (NPO) $252.87
- JBT Marel Corporation (JBTM) $120.50
- The Middleby Corporation (MIDD) $131.67
- Construction Partners, Inc. (ROAD) $69.29
- GXO Logistics, Inc. (GXO) $52.13
- Resideo Technologies, Inc. (REZI) $20.36
- Pony AI Inc. American Depositary Shares (PONY) $3.31
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $925.4M | $860.8M | $800.9M | $717.8M | $668.3M |
| Operating income | $51.5M | $24.8M | -$-21.9M | -$-297.8M | -$-68.7M |
| Net income | $28.8M | -$-36.1M | -$-96.9M | -$-276.9M | -$-222.5M |
| EPSd | $110.3K | -$-176.11K | -$-493.46K | -$-1.53M | -$-1.07M |
| Operating cash flow | $143.3M | $99.1M | $95.2M | $39.4M | $900K |
| Capital expenditure | -$-36.4M | -$-48.8M | -$-37.1M | -$-34.2M | -$-17.6M |
| Free cash flow | $106.9M | $50.3M | $58.1M | $5.2M | -$-16.7M |
| Total assets | $3.59B | $2.64B | $2.72B | $2.74B | $3.12B |
| Total debt | $1.23B | $719.9M | $721M | $849.6M | $860.6M |
| Net debt | $821.4M | $544.7M | $592.2M | $776.1M | $776.6M |
| Total equity | $1.92B | $1.56B | $1.55B | $1.47B | $1.78B |
| Cash and short-term investments | $419.2M | $181.1M | $134.1M | $77.8M | $88.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $925.4M | $860.8M | $800.9M | $717.8M | $668.3M |
| Cost of revenue | $486.8M | $459M | $444.4M | $400.6M | $384.1M |
| Gross profit | $438.6M | $401.8M | $356.5M | $317.2M | $284.2M |
| Research and development expenses | $38.9M | $35M | $31.7M | $30.3M | $36.2M |
| Selling, general and administrative expenses | $348.2M | $338.2M | $338.6M | $357.1M | $267.6M |
| Other expenses | $0.00 | $3.8M | $8.1M | $227.6M | $49.1M |
| Operating expenses | $387.1M | $377M | $378.4M | $615M | $352.9M |
| Cost and expenses | $873.9M | $836M | $822.8M | $1.02B | $737M |
| Interest income | $12.1M | $6.6M | $4.8M | $600K | $145.8M |
| Interest expense | $42.2M | $57.9M | $61.9M | $42.5M | $59M |
| Depreciation and amortization | $138M | $150.4M | $162.8M | $174.5M | $112.2M |
| Ebitda | $212.9M | $179M | $149M | $104.3M | $92.6M |
| Operating income | $51.5M | $24.8M | -$-21.9M | -$-297.8M | -$-68.7M |
| Total other income/expenses, net | -$-18.8M | -$-58.7M | -$-83.4M | -$-8.8M | -$-159.8M |
| Income before tax | $32.7M | -$-33.9M | -$-105.3M | -$-306.6M | -$-228.5M |
| Income tax expense | $2.9M | $2.7M | -$-6.6M | -$-18.2M | -$-5.1M |
| Net income | $28.8M | -$-36.1M | -$-96.9M | -$-276.9M | -$-222.5M |
| Weighted average shares outstanding | $230M | $205M | $196.4M | $181.2M | $208.1M |
| Weighted average diluted shares outstanding | $261.2M | $205M | $196.4M | $181.2M | $208.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $419.2M | $181.1M | $134.1M | $77.8M | $88.9M |
| Net receivables | $290M | $253.3M | $230.4M | $225.6M | $219.7M |
| Inventory | $152.6M | $133.2M | $144.1M | $143.3M | $123.6M |
| Total current assets | $893.7M | $594.7M | $538.6M | $480.6M | $453.4M |
| Property, plant and equipment, net | $187M | $176.6M | $167.4M | $164.9M | $169.7M |
| Goodwill and intangible assets | $2.48B | $1.84B | $1.99B | $2.07B | $2.47B |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $2.69B | $2.04B | $2.18B | $2.23B | $2.66B |
| Total assets | $3.59B | $2.64B | $2.72B | $2.74B | $3.12B |
| Accounts payable | $57.4M | $56.5M | $58.7M | $67.7M | $59.4M |
| Short-term debt | $9.3M | $7.6M | $8.1M | $13.8M | $13.2M |
| Deferred revenue | $131.8M | $110.9M | $103.4M | $83M | $81.8M |
| Total current liabilities | $316.1M | $263.5M | $265.7M | $244.3M | $221M |
| Long-term debt | $1.22B | $712.3M | $712.9M | $835.9M | $847.4M |
| Deferred revenue, non-current | $0.00 | $3M | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.36B | $813.5M | $902.8M | $1.03B | $1.11B |
| Capital lease obligations | $34.5M | $33.5M | $35.1M | $42.9M | $49.9M |
| Total liabilities | $1.67B | $1.08B | $1.17B | $1.27B | $1.33B |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-512.7M | -$-541.5M | -$-505.4M | -$-408.5M | -$-131.6M |
| Accumulated other comprehensive income (loss) | -$-52.6M | -$-93M | -$-65.3M | -$-75.7M | -$-20.7M |
| Total equity | $1.92B | $1.56B | $1.55B | $1.47B | $1.78B |
| Total investments | $6.9M | $5.9M | $5.3M | $4.3M | $4.9M |
| Total debt | $1.23B | $719.9M | $721M | $849.6M | $860.6M |
| Net debt | $821.4M | $544.7M | $592.2M | $776.1M | $776.6M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $28.8M | -$-36.6M | -$-96.9M | -$-288.4M | -$-127.9M |
| Depreciation and amortization | $138M | $150.4M | $162.5M | $174.5M | $62.9M |
| Stock-based compensation | $15.2M | $15.6M | $21.9M | $31.8M | $0.00 |
| Change in working capital | -$-15.7M | -$-26.8M | -$-700K | -$-38.4M | -$-11M |
| Accounts receivable | $6.2M | -$-12M | -$-5M | -$-19.3M | -$-24.3M |
| Inventory | $4M | $1.3M | -$-500K | -$-34.8M | -$-5.1M |
| Accounts payable | -$-10.8M | -$-1.5M | -$-9.9M | $4.5M | $10.3M |
| Net cash provided by operating activities | $143.3M | $99.1M | $95.2M | $39.4M | $900K |
| Investments in property, plant and equipment | -$-36.4M | -$-48.8M | -$-37.1M | -$-34.2M | -$-17.6M |
| Acquisitions, net | -$-661.9M | -$-1M | -$-30.4M | -$-6.6M | -$-2.18B |
| Net cash used for investing activities | -$-694.6M | -$-43.7M | -$-64.7M | -$-39.5M | -$-2.2B |
| Common stock issued | $409.7M | $0.00 | $150M | $0.00 | $860.4M |
| Common stock repurchased | -$-49.6M | -$-2M | -$-1M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $775.9M | -$-3.3M | $22.6M | -$-7M | $1.54B |
| Net change in cash | $239.6M | $45.1M | $55.5M | -$-10.3M | $84.2M |
| Cash at end of period | $415.2M | $175.6M | $130.5M | $75M | $84.6M |
| Operating cash flow | $143.3M | $99.1M | $95.2M | $39.4M | $900K |
| Capital expenditure | -$-36.4M | -$-48.8M | -$-37.1M | -$-34.2M | -$-17.6M |
| Free cash flow | $106.9M | $50.3M | $58.1M | $5.2M | -$-16.7M |
Line items
Line items
Line items
About Mirion Technologies, Inc.
Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).
- CEO
- Thomas D. Logan
- Employees
- 3.28K
- Beta
- 1.03
Explore
Frequently asked questions
What is the intrinsic value of Mirion Technologies, Inc. (MIR)?
Mirion Technologies, Inc. (MIR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MIR undervalued?
MIR trades at a price of $16.07 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.